Actively Recruiting
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Led by West Virginia University · Updated on 2026-04-16
55
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\<100 neutrophils/milliliter) for more than seven days. Xerava™ (eravacycline) has a broad spectrum of activity including many multi-drug resistant strains of bacteria. It is not an agent used for treatment of febrile neutropenia, making eravacycline a very attractive alternative to consider in this prophylactic setting. Eravacycline has activity against MRSA, VRE, and Clostridioides difficile, all of which are common problems in this patient population. It also covers the majority of enteric gram-negative pathogens while also producing satisfactory tissue penetration and adequate plasma concentrations, which has classically been a concern with prior agents. Eravacycline has activity against coagulase-negative staphylococcus, which is a common catheter-related infection in leukemia and HSCT patients. The primary objective will be report the incidence of breakthrough infections during eravacycline prophylaxis for hematologic malignancy patients with prolonged neutropenia.
CONDITIONS
Official Title
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients receiving induction chemotherapy for acute leukemia or preparative regimen for hematopoietic stem cell transplant
- Patient must provide informed consent
- Bilirubin less than or equal to 3 times the upper limit of normal
- AST and ALT less than or equal to 5 times the upper limit of normal
You will not qualify if you...
- Uncontrolled bacterial, viral, or fungal infection at enrollment
- Active treatment for urinary tract infection
- Acute pancreatitis unless symptomatic
- Known allergy to eravacycline or related tetracycline antibiotics
- Pseudomonas infection within 30 days before enrollment
- Use of strong cytochrome P450 3A4 inhibitors or inducers
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aaron Cumpston
Morgantown, West Virginia, United States, 26506
Actively Recruiting
Research Team
A
Aaron Cumpston, PharmD, BCOP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here